The Food and Drug Administration has accepted Lykos Therapeutics’ new drug application for psychedelic-assisted therapy, teeing up 2024 as a potentially transformative year for psychedelic medicine.The FDA granted the application priority review, meaning the agency will review it over six months instead of the standard 10-month timeline. The agency set a target date of Aug. […]
